{"name":"Japan Multinational Trial Organization","slug":"japan-multinational-trial-organization","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"kanamycin/metronidazole","genericName":"kanamycin/metronidazole","slug":"kanamycin-metronidazole","indication":"Bacterial infections, including those caused by anaerobic bacteria and protozoa","status":"phase_3"}]}],"pipeline":[{"name":"kanamycin/metronidazole","genericName":"kanamycin/metronidazole","slug":"kanamycin-metronidazole","phase":"phase_3","mechanism":"Kanamycin is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, while metronidazole is an antimicrobial agent that kills bacteria by interfering with DNA replication.","indications":["Bacterial infections, including those caused by anaerobic bacteria and protozoa"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNdF9tdEdGdVJKUk5LVnBDUmZRSERpV2hWUVUtVzEzUnI1SENnRGVrYXpQNnphTk5aeFJBTnZjbTZQZC0zXy10QVUyTU0tekgwX2lSRjZrelRILWRqaG1ab29wb0dnWUxiRW5NdC1BOEZYcm1zWWxydG1rY0duOEt4YzZMTVhhWXNOTkFVU1pqREpVck1xd1lGaUthVlYxVzN1dXNBNDRIVm5qVTdkcGUzSENoaUhZWHZGVEFPcEVvNA?oc=5","date":"2026-03-16","type":"pipeline","source":"Fortune Business Insights","summary":"CDMO Market Size, Share & Trends | Growth Analysis [2034] - Fortune Business Insights","headline":"CDMO Market Size, Share & Trends | Growth Analysis [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNdlVhelZ4bkdlZV9fRV84WlAyeWJocEgtNUxHYWJvVkFOU1h0UFBIalpKVkNqaF9hd19wV2wyakYxTDZmaGlLZVVudTVsa2hLZDBNb21LTXlYZ29OTURyMU5ScVdyWnhRODRfdy1ZRVNBOWFnMUpDbmM0MFpJbUxrenQzWTgtWm5LQUU2LWdnaE8xNlJ4OTFnQQ?oc=5","date":"2026-02-25","type":"regulatory","source":"The Pharma Letter","summary":"In Japan, regulatory success is built on consultation - The Pharma Letter","headline":"In Japan, regulatory success is built on consultation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNSXBvSjJ0ckFhWDFIZ2k2dENaVkowZGQ3enVNNHpITHNoamVKREEzSXgzSmRJSUEzOXA1S01sSmttMHlUUjNCczJ4TklrSHVoYmlwMm92QnRtT2drNHVBVEM2Z0pxbExKdFdJSnkwSV9IM1RmNm1KcU1sQkVveERDcUpsdTdiTFNGbWJub0FaQ2NiU1ZaNnNQR0ZXZzhNQUYzbjFuZFBLNG5vSko4eUd1TTNfSkxnQWkyZ1hIU2dnMDllQlZWalNMWHNvZ2RHOG9vSFhST09Wc3gwSEkyZjdROVRBcS1GTUk0VHp6U1U2Vlo5YU5qc2xNT0F2LS1HVC1pVTR3NFZsNE13eVJUUThVRGtjMXVTOWs?oc=5","date":"2026-01-07","type":"trial","source":"BioSpace","summary":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - BioSpace","headline":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOdThZM2dIaTVZWjBRWjlmd3FpQjdoWkJSZGJpRW9UUTNqMnhOd0JqdjBrV3JDWFNHbjZKTkt0a19yalJOcG1hLUc0cW0ybkpkR2ZkcHdFRXZjOEg5QUJuWDhSZXYxRDQzRWtLX2VTRkpFUS1aWnJyY1NqM0hEYmlRMU5wOWU3VDF5TF90clBSeGZJSjhZeFY4UGNZd3VzNWRpR1YwQ05ZUnpqT2NhVjdzVjVfem9MY2w0NlJiTktQandUTlFWYzRB?oc=5","date":"2025-12-15","type":"pipeline","source":"BioPharma APAC","summary":"APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage - BioPharma APAC","headline":"APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxNVXZILUREVTFJU1BZaHdRNlZpeWtVMFFRbUFwS0o3dGhyXzN6ejJyYkNLSVZraC1EUFhOcUYtVDRDUUIzUkU0ZEZCdFhpc2gtQnZRbXF5LThXcF85R3lDaEpuMUZKOGhQX05pNW9WUnMxTkJiU0s2amE5bFBXTUFzbkh6b0dTLTgyZ0NPRGkxOHVLc2RfT1F3QVVyeWFSQ2ZHODFzT1ZiTXU4ckphbEZHcTFIbXFPZk1KbDExcWdGc3d5Z1luNk5BX2tQU2V2VzZxYWFrWHZoUGhoVVRFYkRfaWlhWnJnRjlhcGlpQlRBRmo?oc=5","date":"2025-12-02","type":"regulatory","source":"fda.gov","summary":"Interview with MHLW and PMDA leadership - fda.gov","headline":"Interview with MHLW and PMDA leadership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQR1BMVHJZbGtsa18zdE9lWXZINHcyUW9BbmdDN21qdVBaLWp6V29wSEhEU09raUpKajlSM1VrMUZ5NFpScloydWNLeWFkT2hrdkZ5VzFSUUZYUmlqZnNMcXB1ZERWWnU3VVBVdTFMaS10QkJWbUJyb1dzVlJtSnhucEpnM2wyeHBCRHhhOEVNalJyTVZZMkpWdlFJTjFjOE9jRVNJaW5sVGlkbXlETklIUWoyQWxGT25qMTJtdWN5SWppQQ?oc=5","date":"2025-11-29","type":"pipeline","source":"The Worldfolio","summary":"How Meiji Seika Pharma Aims to Lead Global Health With New Vaccines and Antibiotics - The Worldfolio","headline":"How Meiji Seika Pharma Aims to Lead Global Health With New Vaccines and Antibiotics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNd3Z2ZzNLX3hLVW5DQVNXeXpnYXVoQjZQWUhVLUdkZm1oLWROVU5kc0cyMnBNM1Myb1dpamVPaU1iZlhSdEpUMVdKMXBnZTJpTVJqaG1qa0cySkVwRzJXRTdWMVB6cnVCamtyRjFfTVlHQ0IySGZCQXduSzA0cDgwSkdYaXFaWHR1a0YxSWJrb3RmWFNMZFkyQg?oc=5","date":"2025-11-19","type":"pipeline","source":"BioSpace","summary":"CRO Boom in APAC Region, With China at the Forefront - BioSpace","headline":"CRO Boom in APAC Region, With China at the Forefront","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBicGxaeHpZRjRrLUhnRkZTc0I4eld2c2l5Q1dCQjFJdjd5YlJ1UjA2VjMtam10LXhuMDNoUUt2WGdfRFU4cGFES2F0UmxjRkJKU0o1ZFBtQjZDSEpYcFBwakJjbzZxd29vN1lPNUJaRnFZVlhRZlV1Z09jekl1eUk?oc=5","date":"2025-08-29","type":"pipeline","source":"chugai-pharm.co.jp","summary":"Aug 29,2025 | Bringing Innovative Drugs from Japan to the Global Market: The Unique Appeal of Chugai Pharmaceutical's Early Clinical Development｜Stories | CHUGAI PHARMACEUTICAL CO., LTD. - chugai-phar","headline":"Aug 29,2025 | Bringing Innovative Drugs from Japan to the Global Market: The Unique Appeal of Chugai Pharmaceutical's Ea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPbE41eFpTVmEzd2thU0c4Z20zT2lHc1RNMzZiWGlFa3JZNGZuTkdNZi1GZzh5T1pvbjNPTU82dExZczlFUGhNQ3Nmb1MtVTNXa0R6d003TUc1M2pqTWdkcTNGb3AxOHFVSEYzMldyQTVEYmg5bVVSRWhCVVpMYkE4YUpOMVptTEYtWUFrWkdPVDl2TTNOU1ZPRWVVeFFsalpjbHNmemZTZXFzVWJaYkI1UTU4dlp4bjgtOVBSTi1lN3pfbEJtNjVoTTRYVldqUTBH?oc=5","date":"2025-08-21","type":"trial","source":"Reuters","summary":"Japan's Takeda weighs India for global trials to speed up drug launches - Reuters","headline":"Japan's Takeda weighs India for global trials to speed up drug launches","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPeEkxQ3hPOGhmUHg5djFKV3JMX1ZpSHRHQkJKRU5MQzNRRV94eW55VnMtRkcxclNHR21ZNld0MnZUdkZLWUdQLXJOMlVPd19QZERjbFlyOXZGR2Z4TkU0cjBDaGdxb003OUxfZTdTUmM1c1Z4Sk1ZcUdKWVcyMzJLMG5xc2tOWVNEazNCUXdQN3J1QWMwWk5Z?oc=5","date":"2025-08-18","type":"pipeline","source":"Devex","summary":"TICAD spotlight: Japan’s pharma commitment to global health - Devex","headline":"TICAD spotlight: Japan’s pharma commitment to global health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPcWFXNDQ3VXpKLVhKTVFDa2FOZm1Tc1dTUlpHX2NVZTB1NTA5NjFxVWwydjR1Z1VzTjFBS3ZmS0hiOWRULWtleXFBMGMyZWV0YmNTdUNQYW5ZZEY4aU5CVVN5Y0FWRGl5R3ZRemQxN0J0VmcyVEcxeFdpM3B1MTNBNFFwQUhOcTAwcFhmZ0pJVHozekhPTTNqV3NGY1lfR2RRcVlmdGRYaUlnVzZhOGhoMWZVU3VuQzR6RFhIM1ZpNXQ3bnVUb1E?oc=5","date":"2025-08-15","type":"pipeline","source":"The Worldfolio","summary":"How EPNextS Is Driving Innovation in Japan’s Pharmaceutical Landscape Amid Demographic Shifts - The Worldfolio","headline":"How EPNextS Is Driving Innovation in Japan’s Pharmaceutical Landscape Amid Demographic Shifts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9KZkJNOEZHSmVETXQtcnRITkNEbHkwYlJ0R2FKWDdrakhodkcyQzU4MTlBTl9OUS1hUDNwMW44eEowbk96LWxwUHRjdC1ucnpsU2w0SDViR05mUk5hSXNXdllTMjNvMzltaTdXRkJodHVJQQ?oc=5","date":"2025-08-04","type":"pipeline","source":"Wiley","summary":"Expediting Drug Development in Japan: A PMDA Perspective - Wiley","headline":"Expediting Drug Development in Japan: A PMDA Perspective","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}